CD34 and neoplasm: After 3 days of BMS-690514 administration (30 mg kg−1 day−1), the proportion of abnormal tumour vessels seemed to be lesser than that in vehicle-treated controls and a qualitative reduction in CD34-positive vessel area was observed (Figure 5).